Glautam - instructions for use, dose, side effects, contraindications

Active substance: timolol maleate 3.42 mg (timolol in the form of timolol maleate 2.5 mg) Excipients: benzalkonium chloride, sodium dihydrogen phosphate dihydrate, sodium hydrogen sulfate anhydrous, water for injection;

Glutam 5 mg / ml

Active substance: timolol maleate 6.82 mg (timolol in the form of timolol maleate 5.0 mg) Excipients: benzalkonium chloride, sodium dihydrogen phosphate dihydrate, sodium hydrogen sulfate anhydrous, water for injection.

Description:

A clear, colorless solution.

Pharmacotherapeutic group:Antiglaucoma means β-blocker

ATX: & nbsp

S.01.E.D. Beta-blockers

S.01.E.D.01 Timolol

Pharmacodynamics:

Non-selective blocker of beta-adrenergic receptors without SMA. With topical application lowers the intraocular pressure by reducing the formation of watery moisture and a small increase in its outflow. The effect manifests itself 20 minutes after instillation, the maximum effect - after 1-2 hours; the duration of action is 24 hours.

Pharmacokinetics:

Timolol maleate quickly penetrates through the cornea into the tissues of the eye. In an insignificant amount enters the systemic bloodstream by absorption through the conjunctiva, the mucous membranes of the nose and the lacrimal tract. Excretion of metabolites by the kidneys.In newborns and young children, the concentration of the active substance is significantly higher than its C_max in adult plasma.

Indications:

Open angle glaucoma, secondary glaucoma (uveal, aphakic, posttraumatic), acute ophthalmotonus, closed-angle glaucoma (in combination with miotics).

Contraindications:

Bronchial asthma, sinus bradycardia, AV blockade II-III st., Acute and chronic heart failure, cardiogenic shock, dystrophic diseases of the cornea, rhinitis, hypersensitivity to the drug.

Carefully:

Emphysema of the lungs, pulmonary insufficiency, cerebrovascular insufficiency, chronic heart failure, diabetes mellitus, hypoglycemia, thyrotoxicosis, myasthenia gravis, simultaneous administration of other beta-blockers.

Pregnancy and lactation:

In pregnancy, the drug is used if the expected benefit to the mother exceeds the potential risk to the fetus. During the use of the drug, breastfeeding should be discontinued.

Dosing and Administration:

Adults and children older than 1 year are instilled in the conjunctival sac 1 drop 2.5 mg / ml solution 2 times a day, with insufficient effectiveness - 1 drop of 5 mg / ml solution 2 times a day.With the normalization of intraocular pressure, the maintenance dose is 1 drop of 2.5 mg / ml solution once a day.

Side effects:

Local reactions: hyperemia of the skin of the eyelids, burning and itching in the eyes, conjunctival hyperemia, lacrimation or a decrease in teardrop, photophobia, corneal epithelial edema, short-term visual acuity; blepharitis, conjunctivitis, with prolonged use, it is possible to develop a surface point keratopathy

(a decrease in the transparency of the cornea) and a decrease in the sensitivity of the cornea, it is possible ptosis, rarely - diplopia.

Systemic reactions: paresthesia, rhinitis, nasal congestion, epistaxis, lowering of blood pressure, bradycardia, bradyarrhythmia, AV blockade, heart failure, cardiac arrest; decreased myocardial contractility, chest pain, dizziness, headache, drowsiness, hallucinations, muscle weakness, impaired sexual function, decreased potency, transient cerebral circulation, collapse, depression; shortness of breath, bronchospasm, pulmonary insufficiency; nausea, vomiting, diarrhea, allergic reactions (including urticaria).

Overdose:

When topical application in the recommended dose, the symptoms of an overdose were not noted. At casual intake it is possible development of following signs: a nausea, vomiting, a giddiness, a headache, depression of arterial pressure, a bronchospasm, a bradycardia. In case of symptoms of overdose, treatment is symptomatic. Isoprenaline can be administered intravenously to eliminate severe bradycardia or bronchospasm, dobutamine for the treatment of arterial hypotension.

Interaction:

Epinephrine, pilocarpine, systemic beta-blockers increase the effect. When used with reserpine - it is possible to develop severe bradycardia or hypotension (this combination requires careful medical supervision); with calcium channel blockers or cardiac glycosides - there may be a violation of AV conduction, acute left ventricular failure or arterial hypotension. Strengthens the effect of muscle relaxants (timolol should be discontinued 48 hours before the proposed general anesthesia using peripheral muscle relaxants). It can not be used simultaneously with antipsychotic drugs (neuroleptics) and anxiolytic drugs (tranquilizers).During treatment it is not recommended to take ethanol (possibly a sharp drop in blood pressure.

Special instructions:

Control of efficacy should be performed approximately 3-4 weeks after the start of therapy. During the treatment period, at least once every 6 months, the function of lacrimation, the integrity of the cornea, and the field of vision should be monitored.

Contact lenses should be removed before instillation and put on not earlier than 15 minutes after it.

Do not bother with 2 beta-blockers at the same time.

With prolonged use of timolol, the effect may be weakened.

When transferring patients to treatment with timolol, correction of refraction may be necessary.

Before the forthcoming surgical intervention with the application of general anesthesia - within 48 hours the drug should be canceled.

Effect on the ability to drive transp. cf. and fur:Take care when driving at night.

Form release / dosage:

Eye drops 2.5 mg / ml and 5 mg / ml.

Packaging:5 ml of the solution into a transparent polyethylene (LDPE, HDPE) dropper with a white polyethylene (HDPE) cap. One bottle together with instructions for use is placed in a cardboard box.

Storage conditions:

List B.At a temperature of no higher than 25 ° C, in a tightly sealed vial, protected from light, out of reach of children.

Shelf life:

2 years. Shelf life after opening the bottle is 6 weeks. Do not use after the expiration date.

Terms of leave from pharmacies:On prescription

Registration number:LSR-000081/08

Date of registration:21.01.2008

Expiration Date:Unlimited

The owner of the registration certificate:Yadran Galensky Laboratories a.o.Yadran Galensky Laboratories a.o. Croatia

Manufacturer: & nbsp

JADRAN Galenski Laboratorij, d.d. Croatia

Representation: & nbspYadran Galen Laboratory as.Yadran Galen Laboratory as.Croatia

Information update date: & nbsp26.04.2017

Illustrated instructions

Instructions

Glaoutam (Glautam)